669080-86-8

Usage

Uses

Used in Pharmaceutical Industry:
5-[N-(3',5'-BISTRIFLUOROMETHYLBENZYL)AMINO]-2-METHYLTETRAZOLE is used as a key intermediate in the synthesis of various pharmaceuticals for its unique chemical properties and potential to enhance the bioactivity and efficacy of drug molecules.
Used in Medicinal Chemistry Research:
5-[N-(3',5'-BISTRIFLUOROMETHYLBENZYL)AMINO]-2-METHYLTETRAZOLE serves as a valuable compound in medicinal chemistry research, where it can be utilized to explore new drug targets, design novel bioactive molecules, and improve the pharmacokinetic and pharmacodynamic properties of existing drugs.
Used in Drug Development:
5-[N-(3',5'-BISTRIFLUOROMETHYLBENZYL)AMINO]-2-METHYLTETRAZOLE is employed in drug development as a building block for creating new chemical entities with potential therapeutic applications, taking advantage of its unique structural features and chemical reactivity.
Used in Bioactive Compounds Synthesis:
5-[N-(3',5'-BISTRIFLUOROMETHYLBENZYL)AMINO]-2-METHYLTETRAZOLE is used as a starting material in the synthesis of bioactive compounds, leveraging its distinctive chemical properties to develop new molecules with potential applications in various therapeutic areas.

Upstream product

• 6154-04-7 2-methyl-2H-tetrazole-5-amine 
• 5422-44-6 1-methyl-5-amino-1H-tetrazole 
• 401-95-6 3,5-Bis(trifluoromethyl)benzaldehyde 
• 956631-60-0 C₁₁H₇F₆N₅ 

Downstream Products

• 880103-63-9 C₂₆H₂₅F₉N₆O₂ 
• 943551-29-9 [3,5-bis(trifluoromethyl)benzyl](2-chloro-5-trifluoromethylpyridin-3-ylmethyl)(2-methyl-2H-tetrazol-5-yl)amine 
• 1026137-15-4 [3,5-bis(trifluoromethyl)benzyl](2-chloro-7-fluoroquinolin-3-ylmethyl)(2-methyl-2H-tetrazol-5-yl)amine 
• 888738-14-5 N-(2-bromo-5-(trifluoromethyl)benzyl)-N-(3,5-bis(trifluoromethyl)benzyl)-2-methyl-2H-tetrazol-5-amine 
• 888738-22-5 (3,5-bis-trifluoromethyl-benzyl)-(2-bromo-6-trifluoromethyl-pyridin-3-ylmethyl)-(2-methyl-2H-tetrazol-5-yl)-amine 
• 957216-46-5 (3-{[(3,5-bistrifluoromethylbenzyl)(2-methyl-2H-tetrazol-5-yl)amino]methyl}pyridin-2-yl)cyclopentylmethylethylamine 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of n,n-substituted amine derivatives as cholesteryl ester transfer protein inhibitors

N,N-Substituted amine derivatives were designed by utilizing a bioisosterism strategy. Consequently, twenty-two compounds were synthesized and evaluated for their inhibitory activity against CETP. Structure-activity relationship (SAR) studies indicate tha

Development of safe and scalable continuous-flow methods for palladium-catalyzed aerobic oxidation reactions

The synthetic scope and utility of Pd-catalyzed aerobic oxidation reactions has advanced significantly over the past decade, and these reactions have the potential to address important green-chemistry challenges in the pharmaceutical industry. This potential has not been realized, however, because safety concerns and process constraints hinder large-scale applications of this chemistry. These limitations are addressed by the development of a continuous-flow tube reactor, which has been demonstrated on several scales in the aerobic oxidation of alcohols. Use of a dilute oxygen gas source (8% O2 in N 2) ensures that the oxygen/organic mixture never enters the explosive regime, and efficient gas-liquid mixing in the reactor minimizes decomposition of the homogeneous catalyst into inactive Pd metal. These results provide the basis for large-scale implementation of palladium-catalyzed (and other) aerobic oxidation reactions for pharmaceutical synthesis. The Royal Society of Chemistry 2010.

HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS

The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

BICYCLIC DERIVATIVES AS CETP INHIBITORS

The present invention relates to novel compounds of formula (I): or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay

CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS

Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula

Dibenzyl Amine Compounds and Derivatives

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP)

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are as defined, useful as inhibitors of chlosteryl ester transfer protein.

Dibenzyl Amine Compounds and Derivatives

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid le

DIBENZYL AMINE COMPOUNDS AND DERIVATIVES

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid le